Tae Seok Kang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Tae Seok Kang has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Hyung Sik Kim
College of Pharmacy, Pusan National University , Busan, Korea
2 shared publicationsIl Hyun Kang
Health Effects Analysis Team, National Institute of Food and Drug Safety Evaluation, Korea Food and Drug Administration , Seoul, South Korea
2 shared publicationsJung Hee Baek
Health Effects Analysis Team, National Institute of Food and Drug Safety Evaluation, Korea Food and Drug Administration , Seoul, South Korea
2 shared publicationsKi Kyung Jung
Health Effects Analysis Team, National Institute of Food and Drug Safety Evaluation, Korea Food and Drug Administration , Seoul, South Korea
2 shared publicationsSoon Sun Kim
Health Effects Analysis Team, National Institute of Food and Drug Safety Evaluation, Korea Food and Drug Administration , Seoul, South Korea
2 shared publicationsTae Sung Kim
Health Effects Analysis Team, National Institute of Food and Drug Safety Evaluation, Korea Food and Drug Administration, Seoul, South Korea
2 shared publications
Latest Publications
- 1 October 2014
- Published by Elsevier in Food Chemistry
- Vol. 161, 185-191
Dynamic light scattering-based method to determine primary particle size of iron oxide nanoparticles in simulated gastrointestinal fluid
- 1 October 2014
- Published by Elsevier in Food Chemistry
- Vol. 161, 185-191
Dynamic light scattering-based method to determine primary particle size of iron oxide nanoparticles in simulated gastrointestinal fluid
- 13 October 2010
- Published by Taylor & Francis in Journal of Toxicology and Environmental Health, Part A
- Vol. 73 (21-22) , 1544-1559
Effects of in Utero Exposure to DI(n-Butyl) Phthalate on Development of Male Reproductive Tracts in Sprague-Dawley Rats
The purpose of this study was to determine the effects of di(n-butyl) phthalate (DBP) administration on male reproductive organ development in F1 Sprague-Dawley rats following in utero exposure. During gestation days (GD) 10–19, pregnant rats were administered daily, orally, DBP at 250, 500, or 700 mg/kg or flutamide (1, 12.5, or 25 mg/kg/d) as a positive control. The male offspring were sacrificed at 31 d of age. DBP and flutamide dose-dependently significantly increased the incidence of hypospadias and cryptorchidism in F1 male offspring. The weights of testes and accessory sex organs (epididymides, seminal vesicles, ventral prostate, levator ani plus bulbocavernosus muscles (LABC), and Cowper's glands) were significantly reduced in DBP-treated animals. Furthermore, cauda agenesis of epididymides and ventral prostate atrophy were observed in high-dose 700-mg/kg DBP males. Anogenital distance (AGD) and levels of dihydrotestosterone (DHT) and testosterone were significantly decreased in the DBP (700 mg/kg/d)-treated groups. In particular, the expression of androgen receptor (AR) and 5α-reductase type 2 in the proximal penis was markedly depressed following administration of DBP (700 mg/kg/d) or flutamide (25 mg/kg/d). The expression of sonic hedgehog (Shh) in the urethral epithelium of the proximal penis was significantly less in the DBP (700 mg/kg/d)- or flutamide (25 mg/kg/d)-treated groups. In addition, DBP dose-dependently significantly increased the expression of estrogen receptor (ER α) in the undescended testis. Data demonstrated that in utero exposure to DBP produced several abnormal responses in male reproductive organs, and these effects may be due to disruption of the stage-specific expression of genes related to androgen-dependent organs development.
- 13 October 2010
- Published by Taylor & Francis in Journal of Toxicology and Environmental Health, Part A
- Vol. 73 (21-22) , 1544-1559
Effects of in Utero Exposure to DI(n-Butyl) Phthalate on Development of Male Reproductive Tracts in Sprague-Dawley Rats
The purpose of this study was to determine the effects of di(n-butyl) phthalate (DBP) administration on male reproductive organ development in F1 Sprague-Dawley rats following in utero exposure. During gestation days (GD) 10–19, pregnant rats were administered daily, orally, DBP at 250, 500, or 700 mg/kg or flutamide (1, 12.5, or 25 mg/kg/d) as a positive control. The male offspring were sacrificed at 31 d of age. DBP and flutamide dose-dependently significantly increased the incidence of hypospadias and cryptorchidism in F1 male offspring. The weights of testes and accessory sex organs (epididymides, seminal vesicles, ventral prostate, levator ani plus bulbocavernosus muscles (LABC), and Cowper's glands) were significantly reduced in DBP-treated animals. Furthermore, cauda agenesis of epididymides and ventral prostate atrophy were observed in high-dose 700-mg/kg DBP males. Anogenital distance (AGD) and levels of dihydrotestosterone (DHT) and testosterone were significantly decreased in the DBP (700 mg/kg/d)-treated groups. In particular, the expression of androgen receptor (AR) and 5α-reductase type 2 in the proximal penis was markedly depressed following administration of DBP (700 mg/kg/d) or flutamide (25 mg/kg/d). The expression of sonic hedgehog (Shh) in the urethral epithelium of the proximal penis was significantly less in the DBP (700 mg/kg/d)- or flutamide (25 mg/kg/d)-treated groups. In addition, DBP dose-dependently significantly increased the expression of estrogen receptor (ER α) in the undescended testis. Data demonstrated that in utero exposure to DBP produced several abnormal responses in male reproductive organs, and these effects may be due to disruption of the stage-specific expression of genes related to androgen-dependent organs development.
- Open Access
- 1 January 2010
- Published by Japanese Society of Toxicology in The Journal of Toxicological Sciences
- Vol. 35 (2) , 239-243
In vitro study of Organization for Economic Co-operation and Development (OECD) endocrine disruptor screening and testing methods- establishment of a recombinant rat androgen receptor (rrAR) binding assay
The androgen receptor (AR) binding assay can be used to determine the ability of probable endocrine disruptors (EDs) to compete with synthetic androgen methyltrienolone (R1881) for binding to recombinant rat AR (rrAR). In this study, we assessed AR binding of various chemicals using Lexius Freyberger’s method. The rank of relative binding affinity (RBA, IC50) on the tested chemicals was trenbolone 1.3 × 10-8 M (RBA 138) > dihydrotesterone (DHT) 1.8 × 10-8 M (RBA 100) > methyl testosterone 5.7 × 10-8 M (RBA 31.6) > nonylphenol (NP) 1.3 × 10-5 M (RBA 0.14) > bisphenol A (BPA) 1.1 × 10-4 M (RBA 0.016) > isobutyl paraben 3.1 × 10-4 M (RBA 0.0058) > butyl paraben 6.2 × 10-4 M (RBA 0.0029) > propyl paraben 9.7 × 10-4 M (RBA 0.0019). However, di(n-butyl) phthalate (DBP) and di(2-ethylhexyl) phthalate (DEHP), known anti-androgenic chemicals, did not show any significant AR binding activity. Our data suggests that in vitro AR binding assay may be useful as a screening tool for potential EDs.
- 1 January 2010
- Published by Japanese Society of Toxicology in The Journal of Toxicological Sciences
- Vol. 35 (2) , 239-243
Open AccessIn vitro study of Organization for Economic Co-operation and Development (OECD) endocrine disruptor screening and testing methods- establishment of a recombinant rat androgen receptor (rrAR) binding assay
The androgen receptor (AR) binding assay can be used to determine the ability of probable endocrine disruptors (EDs) to compete with synthetic androgen methyltrienolone (R1881) for binding to recombinant rat AR (rrAR). In this study, we assessed AR binding of various chemicals using Lexius Freyberger’s method. The rank of relative binding affinity (RBA, IC50) on the tested chemicals was trenbolone 1.3 × 10-8 M (RBA 138) > dihydrotesterone (DHT) 1.8 × 10-8 M (RBA 100) > methyl testosterone 5.7 × 10-8 M (RBA 31.6) > nonylphenol (NP) 1.3 × 10-5 M (RBA 0.14) > bisphenol A (BPA) 1.1 × 10-4 M (RBA 0.016) > isobutyl paraben 3.1 × 10-4 M (RBA 0.0058) > butyl paraben 6.2 × 10-4 M (RBA 0.0029) > propyl paraben 9.7 × 10-4 M (RBA 0.0019). However, di(n-butyl) phthalate (DBP) and di(2-ethylhexyl) phthalate (DEHP), known anti-androgenic chemicals, did not show any significant AR binding activity. Our data suggests that in vitro AR binding assay may be useful as a screening tool for potential EDs.